` BAX (Baxter International Inc) vs S&P 500 Comparison - Alpha Spread

BAX
vs
S&P 500

Over the past 12 months, BAX has underperformed S&P 500, delivering a return of -24% compared to the S&P 500's 24% growth.

Stocks Performance
BAX vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BAX vs S&P 500

Loading
BAX
S&P 500
Difference

Performance By Year
BAX vs S&P 500

Loading
BAX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Baxter International Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Baxter International Inc
Glance View

Economic Moat
None
Market Cap
15.1B USD
Industry
Health Care

Baxter International Inc. finds its roots in the early 1930s, a time when the healthcare landscape was vastly different. Founded by Donald Baxter, a medical doctor seeking to improve the quality and safety of intravenous therapy, the company initially focused on researching and developing safe ways to provide patients with sterile intravenous solutions. As the years unfolded, Baxter transformed itself from a small operation into a globally recognized healthcare giant. Today, it operates in the realm of lifesaving medical products and services, specializing in the development of essential pharmaceuticals, clinical nutrition for hospitals, advanced kidney care solutions, and critical care technology that healthcare providers depend on daily. Central to Baxter's business model is its commitment to innovation and improving patient outcomes, which drives its success and profitability. By leveraging its expertise in areas like renal and hospital products, Baxter is able to cultivate a diversified portfolio. This diversification not only helps the company mitigate risks but also strengthens its market position. Revenue streams are generated through the manufacture and sale of medical devices and pharmaceuticals, catering mostly to hospitals, clinics, and renal care centers worldwide. Baxter consistently reinvests in its research and development, aiming to pioneer novel therapies and products that address the evolving needs of the healthcare sector, ensuring that it remains a key player in the ongoing story of medical progress.

BAX Intrinsic Value
47.94 USD
Undervaluation 38%
Intrinsic Value
Price
Back to Top